Physician profile
Fiona Van
NPI 1760104160
$2,237.07
in general payments reported to CMS, 2019-2025
11 companies · $562 in 2025
The $562 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $32.30 · 2023: $842 · 2024: $801 · 2025: $562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,204.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $526.06 | 2023-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $388.21 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Exact Sciences Corporation | $288.78 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $214.28 | 2023-2025 | Jardiance, Tradjenta, Synjardy |
| Novo Nordisk INC | $209.86 | 2022-2025 | Rybelsus, Ozempic |
| Gilead Sciences, INC. | $203.99 | 2023-2025 | |
| Lilly USA, LLC | $152.45 | 2022-2025 | Mounjaro, Jardiance, Emgality |
| Glaxosmithkline, LLC. | $112.78 | 2024-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $90.56 | 2024-2025 | Veozah |
| Vbi Vaccine (Delaware) INC. | $27.56 | 2023 | Prehevbrio |
| Phadia US INC. | $22.54 | 2024 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fiona Van listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.